vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and CRYO CELL INTERNATIONAL INC (CCEL). Click either name above to swap in a different company.
Axil Brands, Inc. is the larger business by last-quarter revenue ($8.1M vs $7.8M, roughly 1.0× CRYO CELL INTERNATIONAL INC). Axil Brands, Inc. runs the higher net margin — 8.7% vs -48.7%, a 57.3% gap on every dollar of revenue. On growth, Axil Brands, Inc. posted the faster year-over-year revenue change (5.2% vs -2.3%). CRYO CELL INTERNATIONAL INC produced more free cash flow last quarter ($1.2M vs $906.4K). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs -0.1%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.
AXIL vs CCEL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $7.8M |
| Net Profit | $704.9K | $-3.8M |
| Gross Margin | 68.1% | 77.9% |
| Operating Margin | 11.1% | -50.6% |
| Net Margin | 8.7% | -48.7% |
| Revenue YoY | 5.2% | -2.3% |
| Net Profit YoY | 11.2% | -105.1% |
| EPS (diluted) | $0.09 | $-0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $7.8M | ||
| Q3 25 | $6.9M | $7.8M | ||
| Q2 25 | $5.8M | $7.9M | ||
| Q1 25 | $6.9M | $8.0M | ||
| Q4 24 | $7.7M | $8.0M | ||
| Q3 24 | $5.9M | $8.1M | ||
| Q2 24 | $6.5M | $8.0M | ||
| Q1 24 | $6.5M | $7.9M |
| Q4 25 | $704.9K | $-3.8M | ||
| Q3 25 | $334.3K | $749.4K | ||
| Q2 25 | $-245.6K | $355.8K | ||
| Q1 25 | $576.7K | $282.9K | ||
| Q4 24 | $633.7K | $-1.9M | ||
| Q3 24 | $-109.8K | $1.1M | ||
| Q2 24 | $49.5K | $655.8K | ||
| Q1 24 | $781.1K | $556.2K |
| Q4 25 | 68.1% | 77.9% | ||
| Q3 25 | 67.6% | 77.0% | ||
| Q2 25 | 70.0% | 76.6% | ||
| Q1 25 | 71.7% | 75.1% | ||
| Q4 24 | 71.1% | 78.4% | ||
| Q3 24 | 71.0% | 73.6% | ||
| Q2 24 | 71.5% | 74.8% | ||
| Q1 24 | 71.5% | 73.7% |
| Q4 25 | 11.1% | -50.6% | ||
| Q3 25 | 6.0% | 24.3% | ||
| Q2 25 | 0.8% | 18.8% | ||
| Q1 25 | 8.4% | 13.3% | ||
| Q4 24 | 8.7% | -1.5% | ||
| Q3 24 | -2.4% | 17.2% | ||
| Q2 24 | 2.6% | 17.3% | ||
| Q1 24 | -1.6% | 10.5% |
| Q4 25 | 8.7% | -48.7% | ||
| Q3 25 | 4.9% | 9.6% | ||
| Q2 25 | -4.3% | 4.5% | ||
| Q1 25 | 8.3% | 3.5% | ||
| Q4 24 | 8.2% | -23.2% | ||
| Q3 24 | -1.9% | 13.0% | ||
| Q2 24 | 0.8% | 8.2% | ||
| Q1 24 | 12.1% | 7.1% |
| Q4 25 | $0.09 | $-0.46 | ||
| Q3 25 | $0.04 | $0.09 | ||
| Q2 25 | $-0.03 | $0.04 | ||
| Q1 25 | $0.07 | $0.03 | ||
| Q4 24 | $0.08 | $-0.23 | ||
| Q3 24 | $-0.02 | $0.13 | ||
| Q2 24 | $0.11 | $0.08 | ||
| Q1 24 | $0.04 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $3.3M |
| Total DebtLower is stronger | $138.3K | $8.4M |
| Stockholders' EquityBook value | $11.1M | $-18.6M |
| Total Assets | $16.2M | $61.7M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $3.3M | ||
| Q3 25 | $4.1M | $3.2M | ||
| Q2 25 | $4.8M | $4.4M | ||
| Q1 25 | $4.7M | $3.5M | ||
| Q4 24 | $5.2M | $3.5M | ||
| Q3 24 | $4.1M | $2.1M | ||
| Q2 24 | $3.3M | $1.5M | ||
| Q1 24 | $4.9M | $979.6K |
| Q4 25 | $138.3K | $8.4M | ||
| Q3 25 | $139.2K | $8.4M | ||
| Q2 25 | $140.2K | $8.4M | ||
| Q1 25 | $141.0K | $8.5M | ||
| Q4 24 | $143.3K | $8.5M | ||
| Q3 24 | $144.3K | $8.5M | ||
| Q2 24 | $146.6K | $8.5M | ||
| Q1 24 | — | $8.6M |
| Q4 25 | $11.1M | $-18.6M | ||
| Q3 25 | $10.2M | $-14.8M | ||
| Q2 25 | $9.7M | $-15.6M | ||
| Q1 25 | $9.7M | $-14.7M | ||
| Q4 24 | $8.8M | $-13.2M | ||
| Q3 24 | $7.9M | $-9.6M | ||
| Q2 24 | $7.7M | $-10.7M | ||
| Q1 24 | $8.8M | $-10.3M |
| Q4 25 | $16.2M | $61.7M | ||
| Q3 25 | $15.4M | $63.2M | ||
| Q2 25 | $12.9M | $64.4M | ||
| Q1 25 | $13.0M | $64.4M | ||
| Q4 24 | $13.7M | $64.7M | ||
| Q3 24 | $11.4M | $62.9M | ||
| Q2 24 | $11.0M | $62.6M | ||
| Q1 24 | $12.7M | $61.7M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $1.3M |
| Free Cash FlowOCF − Capex | $906.4K | $1.2M |
| FCF MarginFCF / Revenue | 11.1% | 15.5% |
| Capex IntensityCapex / Revenue | 0.3% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $1.3M | ||
| Q3 25 | $-739.2K | $2.5M | ||
| Q2 25 | $194.4K | $707.0K | ||
| Q1 25 | $-169.9K | $954.1K | ||
| Q4 24 | $1.0M | $2.2M | ||
| Q3 24 | $897.3K | $2.4M | ||
| Q2 24 | $-336.6K | $1.8M | ||
| Q1 24 | $-912.8K | $-356.9K |
| Q4 25 | $906.4K | $1.2M | ||
| Q3 25 | $-747.6K | $2.5M | ||
| Q2 25 | — | $644.6K | ||
| Q1 25 | $-258.2K | $892.0K | ||
| Q4 24 | $941.1K | $2.1M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | $-394.9K | $21.5K | ||
| Q1 24 | $-922.1K | $-814.6K |
| Q4 25 | 11.1% | 15.5% | ||
| Q3 25 | -10.9% | 31.9% | ||
| Q2 25 | — | 8.1% | ||
| Q1 25 | -3.7% | 11.2% | ||
| Q4 24 | 12.2% | 26.8% | ||
| Q3 24 | — | 27.9% | ||
| Q2 24 | -6.1% | 0.3% | ||
| Q1 24 | -14.3% | -10.4% |
| Q4 25 | 0.3% | 0.9% | ||
| Q3 25 | 0.1% | 0.5% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | 1.3% | 0.8% | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | 0.9% | 21.8% | ||
| Q1 24 | 0.1% | 5.8% |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | 3.38× | ||
| Q2 25 | — | 1.99× | ||
| Q1 25 | -0.29× | 3.37× | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | 2.32× | ||
| Q2 24 | -6.80× | 2.70× | ||
| Q1 24 | -1.17× | -0.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
CCEL
Segment breakdown not available.
